J&J Resolves 5 Risperdal Off-Label Marketing Cases
Johnson & Johnson agreed Thursday to settle five cases it was facing in Pennsylvania state court alleging the antipsychotic drug Risperdal was illegally marketed to children and caused abnormal breast growth...To view the full article, register now.
Already a subscriber? Click here to view full article